Silver oxide (Ag2O)
CAS 20667-12-3
Silver oxide (Ag2O) (CAS 20667-12-3) is a pharmaceutical compound with 0 bioactivity targets and 22 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Silver oxide (Ag2O) is linked to DTXSID40893897 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Silver oxide (Ag2O) used for in pharmaceutical contexts?
Silver oxide (Ag2O) (CAS 20667-12-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Silver oxide (Ag2O)?
Silver oxide (Ag2O) has 22 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Device issue, Dysphagia, Fall, Heart failure with reduced ejection fraction, Hypervolaemia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Silver oxide (Ag2O) also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Silver Hydroxide with EU status "restricted".
What clinical phase is Silver oxide (Ag2O) in?
No phase 1-4 clinical development badge is rendered for Silver oxide (Ag2O) because the matched compound identifier rows do not contain a max-phase value.